The pathophysiology of aldosterone in the cardiovascular system

Annals of the New York Academy of Sciences

Volumn 970, Issue , 2002, Pages 89-100

  Rocha, Ricardo ^a   Funder, John W ^b  

^a PFIZER INC   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Aldosterone; Angiotensin II; Eplerenone; Hypertension; Mineralocorticoids

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; EPLERENONE; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OXPRENOATE POTASSIUM; POTASSIUM; SODIUM;

ADRENALECTOMY; ANIMAL MODEL; BRAIN; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; EPITHELIUM; EXPERIMENTAL MODEL; HEART DISEASE; HEART FAILURE; HORMONE ACTION; HUMAN; HYPERTENSION; KIDNEY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POTASSIUM EXCRETION; SODIUM RETENTION; VASCULAR DISEASE;

ANIMALIA;

EID: 0037024518     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04415.x     Document Type: Conference Paper

References (50)

1. Trapp, T. & F. Holsboer. 1995. Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem. Biophys. Res. Commun. 215: 286-291.
2. Fejes-Toth, G., D. Pearce & A. Naray-Fejes-Toth. 1998. Subcellular localization of mineralocorticoid receptors in living cells: Effects of receptor agonists and antagonists. Proc. Natl. Acad. Sci. USA. 95: 2973-2978.
3. Chen, S.Y., A. Bhargava, L. Mastroberardino, et al. 1999. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc. Natl. Acad. Sci. USA. 96: 2514-2519.
4. Bhargava, A., M.J. Fullerton, K. Myles, et al. 2001. The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. Endocrinology 142: 1587-1594.
5. Rocha, R. & C.T. Stier, Jr. 2001. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol. Metab. 12: 308-314.
6. Lombes, M., N. Alfaidy, E. Eugene, et al. 1995. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 92: 175-182.
7. Roland, B.L., Z.S. Krozowski & J.W. Funder. 1995. Glucocorticoid receptor, mineralocorticoid receptors, 11 beta- hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: In situ studies. Mol. Cell Endocrinol. 111: R1-7.
8. Takeda, Y., I. Miyamori, S. Inaba, et al. 1997. Vascular aldosterone in genetically hypertensive rats. Hypertension 29(1 Pt 1): 45-48.
9. Gomez-Sanchez, C.E., M.Y. Zhou, E.N. Cozza, et al. 1997. Aldosterone biosynthesis in the rat brain. Endocrinology 138: 3369-3373.
10. Silvestre, J.S., V. Robert, C. Heymes, et al. 1998. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 273: 4883-4891.
11. Sato, A. & T. Saruta. 2001. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res. 29: 13-21.
12. Struthers, A.D. 1996. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Fail. 2: 47-54.
13. Pitt, B. 1995. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc. Drugs Ther. 9: 145-149.
14. Borghi, C., S. Boschi, E. Ambrosioni, et al. 1993. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J. Clin. Pharmacol. 33: 40-45.
15. Hall, J.E., J.P. Granger, M.J. Smith, Jr. & A.J. Premen. 1984. Role of renal hemodynamics and arterial pressure in aldosterone "escape." Hypertension 6(2 Pt 2): I183-192.
16. Lifton, R.P., R.G. Dluhy, M. Powers, et al. 1992. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355: 262-265.
17. Litchfield, W.R., R.G. Dluhy, R.P. Lifton & G.M. Rich. 1995. Glucocorticoid-remediable aldosteronism. Compr. Ther. 21: 553-558.
18. Rich, G.M., S. Ulick, S. Cook, et al. 1992. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann. Intern. Med. 116: 813-820.
19. Rayner, B.L., J.E. Myers, L.H. Opie, et al. 2001. Screening for primary aldosteronism-normal ranges for aldosterone and renin in three South African population groups. S. Afr. Med. J. 91: 594-599.
20. Ganguly, A. 2001. Prevalence of primary aldosteronism in unselected hypertensive populations: Screening and definitive diagnosis. J. Clin. Endocrinol. Metab. 86: 4002-4004.
21. Rayner, B.L., L.H. Opie & J.S. Davidson. 2000. The aldosterone/renin ratio as a screening test for primary aldosteronism. S. Afr. Med. J. 90: 394-400.
22. Loh, K.C., E.S. Koay, M.C. Khaw, et al. 2000. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 85: 2854-2859.
23. Nishikawa, T. & M. Omura. 2000. Clinical characteristics of primary aldosteronism: Its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed. Pharmacother. 54 (Suppl. 1): 83s-85s.
24. Fardella, C.E., L. Mosso, C. Gomez-Sanchez, et al. 2000. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J. Clin. Endocrinol. Metab. 85: 1863-1867.
25. Lim, P.O., E. Dow, G. Brennan, et al. 2000. High prevalence of primary aldosteronism in the Tayside Hypertension Clinic population. J. Hum. Hypertens. 14: 311-315.
26. Lim, P. O., P. Rodgers, K. Cardale, et al. 1999. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 353: 40.
27. Abdelhamid, S., H. Muller-Lobeck, S. Pahl, et al. 1996. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch. Intern. Med. 156: 1190-1195.
28. Rossi, G.P., A. Sacchetto, P. Visentin, et al. 1996. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 27: 1039-1045.
29. Halimi, J.M. & A. Mimran. 1995. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J. Hypertens. 13(12 Pt 2): 1801-1802.
30. Takeda, R., T. Matsubara, I. Miyamori, et al. 1995. Vascular complications in patients with aldosterone producing adenoma in Japan: Comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. Jpn. Endocrinol. Invest., 18: 370-373.
31. Pitt B., F. Zannad, W. J. Remme, et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341: 709-717.
32. Takeda, Y., T. Yoneda, M. Demura, et al. 2000. Cardiac aldosterone production in genetically hypertensive rats. Hypertension. 36: 495-500.
33. Mizuno, Y., M. Yoshimura, H. Yasue, et al. 2001. Aldosterone production is activated in failing ventricle in humans. Circulation 103: 72-77.
34. Silvestre, J.S., C. Heymes, A. Oubenaissa, et al. 1999. Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99: 2694-2701.
35. Kayes-Wandover, K.M. & P. C. White. 2000. Steroidogenic enzyme gene expression in the human heart. J. Clin. Endocrinol. Metab. 85: 2519-2525.
36. Young, M.J., C.D. Clyne, T.J. Cole & J.W. Funder. 2001. Cardiac steroidogenesis in the normal and failing heart. J. Clin. Endocrinol. Metab. 86: 5121-5126.
37. Brilla, C.G. & K.T. Weber. 1992. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc. Res. 26: 671-677.
38. Brilla, C.G., R. Pick, L.B. Tan, et al. 1990. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 67: 1355-1364.
39. Rocha, R., C.T. Stier, Jr., I. Kifor, et al. 2000. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878.
40. Fiebeler, A., F. Schmidt, D.N. Muller, et al. 2001. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 37 (2 Part 2): 787-793.
41. Friedman, S.M. & C.L. Friedman. 1948 Observations on the role of the rat kidney in hypertension caused by deoxycorticosterone acetate. J. Exp. Med.: 87: 329.
42. Selye, H. 1946. The general adaptation syndrome and the diseases of adaptation. J. Clin. Endocrinol. 6: 117-230.
43. Rocha, R., A.E. Rudolph, G.E. Frierdich, et al. 2002. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283: in press.
44. Sabbah, H.N., G. Suzuki, H. Morita, et al. 2002. Eplerenone, a novel aldosterone receptor antagonist, prevents progressive left ventricular dysfunction and attenuates remodeling in dogs with heart failure. Presented at the 66th Annual Scientific Meeting of the Japanese Circulation Society, Sapporo, Japan, April 26.
45. Gomez-Sanchez, E.P., M.T. Venkataraman, D. Thwaites & C. Fort. 1990. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 258 (4 Pt 1): E649-653.
46. Sakai, R.R., B.S. McEwen, S.J. Fluharty & L.Y. Ma. 2000. Amygdala: Site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 57: 1337-1345.
47. Rocha, R. & C.T. Stier. 2002. Role of aldosterone in the development of stroke in genetically hypertensive rats. Presented at the 66th Annual Meeting of the Japanese Circulation Society, Sapporo, Japan, April 24.
48. Rocha, R., P.N Chander, K. Khanna, et al. 1998. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 31 (1 Pt 2): 451-458.
49. Rocha, R., P.N. Chander, A. Zuckerman, et al. 1999. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 33 (1 Pt 2): 232-237.
50. Weber, K.T. 2001. Aldosterone in congestive heart failure. N. Engl. J. Med. 345: 1689-1697.